Navigation Links
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Date:1/13/2009

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care-

NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comparable to a current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin) in the first-line treatment of advanced (metastatic) colorectal cancer.

In the study, patients receiving XELOX lived for a median of 19.0 months, while patients receiving FOLFOX-4 lived for a median of 18.5 months. The consistency of these results were also further demonstrated in a subset population from the original two-arm part of the study (XELOX v. FOLFOX). These data will be presented later this week at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, Calif.

"These compelling data validate previous studies showing that XELOX is comparable to FOLFOX-4 for the treatment of advanced colorectal cancer, while providing the added flexibility of the proven oral component Xeloda," said Edward Chu, M.D., chief of medical oncology, Yale Cancer Center. "Together, these studies confirm the value and importance of combination therapy with oral Xeloda for the thousands of patients with this insidious disease."

Colorectal cancer is the third most common cancer in the United States. The American Cancer Society estimated that in 2008 more than 148,000 people in the U.S. would be diagnosed and about 50,000 people would die from the disease. (1)

Previous data reported from the NO16966 study showed that XELOX is comparable to FOLFOX-4 in terms of progression-free survival, and the addition of Avastin to chemotherapy (FOLFOX-4 and XELOX) significantly improved progression-free survival by investigator assessment compared to chemotherapy alone. Fu
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
2. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
3. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
6. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
7. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
8. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
9. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
10. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...stCall/ -- Volcano Corporation (Nasdaq: VOLC ), a...of products for the diagnosis and treatment of cor...at it will be participating in the Third Annual Ca...mber 10. ,, The presentation by Scott Huenneken...in at 1 p.m., Pacific Standard Time (4 p.m., Easte...
(Date:11/9/2009)...a., Nov. 9 Hill-Rom (N...e formation of a joint venture that will focus on ... of surface replacement systems that are intended ...ements for surfaces that are technologically obsol... a global leader in patient support systems and re...
(Date:11/9/2009)...Asia-FirstCall/ -- American Oriental,Bioengineerin...a pharmaceutical,company dedicated to improving he...ercialization of a broad range of prescription and...d that it plans to release third quarter 2009,fina...the market closes. , The Company will hol...
Breaking Medicine Technology:Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 2Hill-Rom and Encompass Group Form Joint Venture 2Hill-Rom and Encompass Group Form Joint Venture 3Hill-Rom and Encompass Group Form Joint Venture 4Hill-Rom and Encompass Group Form Joint Venture 5New Drug Could Work Against Leukemia 50663 1Sexist jokes favor the mental mechanisms that justify violence against women 50661 1Sexist jokes favor the mental mechanisms that justify violence against women 50661 2Center receives grant renewal for hypertension and vascular disease studies 50659 1Center receives grant renewal for hypertension and vascular disease studies 50659 2
...t. 31 United,Therapeutics Corporation (Nasdaq: U...., announced today that they will release the resu... inhaled formulation of treprostinil,in pulmonary ...Thursday,November 1, 2007. United Therapeutics wi... on November 1, 2007, to a full hour to accommodat...
...stal Research,Associates, LLC announced today that...(R) (EIO(R)) on CEL-SCI Corporation (Amex: CVM )....ww.crystalra.com . CEL-SCI Corporation develops i...s. Its primary product candidate is Multikine(R), ...t targets treatment-naive,newly diagnosed head and...
Other Medicine Technology:Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 3
(Date:11/10/2009)...zerland, Nov. 10 ,, ... Q4 2009 Q4 2008 % Change FY 2...-- ------- -------- ------- ------- --------, ...$17,237 $20,199 (15)%, Income (Loss) from,... $264 (22)% ($1,833) $1,095 -, Di...
(Date:11/10/2009)... At a time when health is a major concern for man...uncertain, Easy Pha-max, an internationally recogn...tates. Consumers now have more options to consider...t better time to have options than now. Easy Pha-m...al products that can address many health concerns ...
(Date:11/10/2009)... It is now possible to achieve exceptionally smoo... of hard materials such as ceramics, carbide and h...he new Diamond Flex-Hone® honing tool from B... Los Angeles (PRWEB) November 10, 2009 -- Using ...ed to the ends of flexible filaments, the Diamond ...
(Date:11/9/2009)... Businesses of all sizes looking to fast-track pr...mic have a new resource at their disposal. , ...9, 2009 -- Human resource (HR) professionals looki... for the H1N1 pandemic have a new resource at thei...nter for Infectious Disease Research and Policy (C...
(Date:11/9/2009)...a, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Mindray M...ng developer, manufacturer and,marketer of medical...naudited,financial results for the third quarter a...ighlights for Operations as of September 30, 2009,... million, an increase of, 3.1% over the thir...
Breaking Medicine News(10 mins):Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 2Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 3Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 4Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 5Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 6Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 7Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 8Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 9Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 10Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 11Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 12Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 13Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 14Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 15Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 16Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 17Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 18Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 19Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 20Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 21Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 22Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 23Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 24Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 25Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 26Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 27Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 28Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 29Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 30Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 31Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 32Health News:Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share 33Health News:Major Biotechnology Franchise Company Expands Rapidly Throughout the USA Amidst Mounting Health Concerns 2Health News:Diamond Honing Tool Technology: The New Standard in Surface Finishing of Hard Materials 2Health News:New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 2
...stitute (NHLBI) of the National Institutes of Heal...ng North American clinical trial of diabetes and c...y concerns after review of available data, althoug... to intensively lower blood glucose (sugar) below ...
... mark,its 10th anniversary of delivering identity ...industry, Sentillion, the company that created hea...r-end results. In Q4, Sentillion,added 10 new cust...ity and access management products for single,sign...
...t Increase in Sales from Same ... Greenway Medical Technologies,Inc., a leading pr...R),practice management and interoperability functi...me period in fiscal 2007,and 83 percent from the s...
...out suspected cancer-causing agents, such as deodo...sessment tool has been developed through the Cance...rra Health (SESIH) by a University of New South Wa...y such as using deodorants, artificial sweeteners ...
...es, constructed with soft lithography, should boos...re brain-behavior connections and to screen new ph... infections in humans, report 10 scientists at thr...iled in a paper appearing online ahead of regular ...
...Inc., a global,supplier of infant formulas and nut...anies to accommodate its growing number of interna... into Asia, where it formed PBM,(Guangzhou) Nutrit...007,the magazine,s annual ranking of America,s fas...
Other Medicine News:Health News:Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 2Health News:Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 3Health News:Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 4Health News:Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 5Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 2Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 3Health News:Greenway Medical Technologies Continues Record Setting Growth 2Health News:Greenway Medical Technologies Continues Record Setting Growth 3Health News:Greenway Medical Technologies Continues Record Setting Growth 4Health News:Reducing cancer panic 2Health News:New devices to boost nematode research on neurons and drugs 2Health News:New devices to boost nematode research on neurons and drugs 3
Access Vitamin B12
Quantaphase II B12/RIA
Autoimmunity Screening Panel 1
...ies that have decided to change to the ELISA metho...A ANAs correlation with IFA and many user friendly...n. While no ELISA ANA currently on the market is c...A screen has been shown to be quite effective at d...
Medicine Products: